Nursing Education for Remdesivir

- Antiviral
- Authorized for emergency use in the United States and administered intravenously by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. Severe disease is defined as patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator.
- Ordering is restricted to Infectious Disease only
- Adult Administration:
    - Usual adult dose is 200mg on day 1 followed by 100mg daily for 9 days for patients on mechanical ventilation, or 200mg on day 1 followed by 100mg daily for 4 days for patient not on a vent.
    - The prescriber may continue remdesivir for an additional 5 days (total of 10 days' treatment) for non-vented patients at their discretion.
    - Administer as an IV infusion of 250mL over 120 minutes. Flush line with at least 30 mL NS after remdesivir infusion is complete
    - Pharmacy will mix medication and prime tubing with normal saline prior to administration.
- *****Important Information *****
    - Patient or designee must receive patient information prior to administration of the drug; Fact Sheet for Patients (Available in English and Spanish); To be printed directly from link in order.
    - Patient or designee must be aware that drug is not FDA approved and they may decline the use of the drug if they wish
    - Patient or designee must sign ***Informed Consent for Remdesivir.***
        - Specific consent can be printed directly from link in order. After consent has been signed, it will need to be scanned and uploaded into Epic.
        - Ordering provider (Infection Disease physician) will obtain and must sign the consent
- Adverse Reactions:
    - Hepatic: Increased serum alanine aminotransferase (FDA 2020a), increased serum aspartate aminotransferase (FDA 2020a)
    - Miscellaneous: Infusion related reaction (including hypotension, nausea, vomiting, diaphoresis, and shivering) (FDA 2020a)
- Warnings/Precautions
    - Pharmacy will monitor labs daily prior to dispensing medication
    - If infusion reactions occur, discontinue administration and institute appropriate treatment if a clinically significant reaction and notify provider immediately
- Monitoring
    - CMP x1 at baseline and Daily x10
    - Signs and symptoms of infusion reaction
- Excretion: Urine-74% (majority as metabolites); Feces-18%

- Special Considerations
  - ***Remdesivir will be handled as a hazardous drug at SIH***
  - ***Chemo precautions (Below are the instructions for ordered chemo precautions)***



Has your patient had chemo in the last 72 hours?

~~If the answer is *YES*, call the Med Once office at 68374 from 0800 – 1700.~~ After hours, notify the Oncologist by Perfect Serve.

- Place patient on **chemo precautions** in a single private room. Chemo precautions include obtaining a chemo cart at MHC by calling central supply or Pharmacy at 35440 at HH, or a chemo bucket at SJMH by calling house supervisor at 55426.
- Precautions include - wearing a gown and double gloves if handling body fluids, and wearing a pair of goggles for splash hazard. Body fluids include urine, feces, sweat, tears, saliva, emesis, or any mucus secretions.
- If body fluids need to be flushed, please carry the container, covered with a towel to the toilet. Close the lid and always flush twice, then clean the toilet with bleach and it is now clean for the next patient.
- Use the chemo spill kit for spilled body fluids. The directions are included in the kit.
- ~~Call the office regarding dosifuser pumps.~~
- No pregnant nurses assigned to chemo patients.
- ~~If any patient has seen an Oncologist for any appointment in the last 2 weeks, please notify the Oncologist.~~

PPE

Body fluid disposal

No need to call oncology

  - ***Disposal: Yellow Chemo or Black bins***
  - ***IV Compatibilities: Unknown (Should only run with plain saline)***

References

Gilead. (2020). Fact sheet for healthcare provider's emergency use authorization (EUA) of Remdesivir (GS-5734™). Retrieved from https://www.gilead.com/-/media/files/pdfs/remdesivir/eua-fact-sheet-for-hcps_01may2020.pdf?la=en&hash=B56F8C441364B7EDA15543F75E8EC88F

Lexicomp. (2020). Remdesivir. Retrieved from http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6925182?searchUrl=%2Flco%2Faction%2Fsearch%3Bjsessionid%3DB8720165D9259F0270809342212547B0%3Forigin%3Dapi%26t%3Dglobalid%26q%3D869929%26nq%3Dtrue

Up to Date. (2020). Remdesivir (United States: Investigational agent; refer to Prescribing and Access Restrictions): Drug information. Retrieved from https://www.uptodate.com/contents/remdesivir-united-states-investigational-agent-refer-to-prescribing-and-access-restrictions-drug-information?search=remdesivir&source=panel_search_result&selectedTitle=1~17&usage_type=panel&kp_tab=drug_general&display_rank=1